-
Immunometabolism in systemic lupus erythematosus Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-06-16 Eduardo Patiño-Martinez, Mariana J. Kaplan
-
Methotrexate does not improve knee OA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-06-10 Sarah Onuora
In the MESKO clinical trial, treatment with low-dose methotrexate did not improve pain or joint inflammation in individuals with inflammatory knee osteoarthritis.
-
Methotrexate as first-line therapy for pulmonary sarcoidosis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-06-10 Sarah Onuora
The results of a new clinical trial suggest that methotrexate could be an alternative to prednisone as first-line treatment for pulmonary sarcoidosis.
-
2023 International Rome consensus for the nomenclature of Sjögren disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-06-10 Manuel Ramos-Casals, Alan N. Baer, María del Pilar Brito-Zerón, Katherine M. Hammitt, Coralie Bouillot, Soledad Retamozo, Alison Mackey, David Yarowsky, Breck Turner, Jaime Blanck, Benjamin A. Fisher, Esen K. Akpek, Chiara Baldini, Hendrika Bootsma, Simon J. Bowman, Thomas Dörner, Leslie Laing, Scott M. Lieberman, Xavier Mariette, Stephen C. Pflugfelder, Vidya Sankar, Antoni Sisó-Almirall, Athanasios
-
Clonal dominance: mutations in VEXAS syndrome take advantage of inflammation Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-06-06 Samuel J. Magaziner, David B. Beck
-
Advances in the treatment of ANCA-associated vasculitis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-06-05 Giorgio Trivioli, Marta Casal Moura, Andreas Kronbichler, Rona M. Smith, Benjamin Terrier, Stephen McAdoo, Rachel B. Jones, Peter A. Merkel, David R. W. Jayne
-
Insights into Lyme arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-05-28 Holly Webster
Two complimentary studies provide a deeper understanding of Lyme disease and the associated chronic complications, such as Lyme arthritis.
-
How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-05-16 Vibeke Strand
The increased incidence of deep vein thromboses and pulmonary emboli has long been noted in rheumatoid arthritis and has been ascribed to the effects of chronic inflammation and disease activity, as well as to specific biologic DMARDs and JAK inhibitors. Reporting in ACR Open Rheumatology, Zavoriti and Miossec provide data that might explain the prothrombotic effects of the JAK inhibitor tofacitinib
-
The pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-05-14 Ahmet Gül, Ivona Aksentijevich, Paul Brogan, Marco Gattorno, Peter C. Grayson, Seza Ozen
-
Fibroblasts in immune responses, inflammatory diseases and therapeutic implications Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-05-14 Angela E. Zou, Suppawat Kongthong, Alisa A. Mueller, Michael B. Brenner
-
Region-specific, data-driven guidelines are needed for rheumatic diseases in LMICs Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-05-12 Amita Aggarwal
Separate guidelines are needed for the management and diagnosis of rheumatic diseases in low- and middle-income countries, especially with the advent of expensive biological therapies and monitoring techniques. The lack of robust data on the efficacy of low-cost drugs and biosimilars in these countries limits the development of data-driven guidelines.
-
Understanding rheumatic disease through continuous cell state analysis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-05-07 Lysette Marshall, Soumya Raychaudhuri, Sebastien Viatte
-
Arterial and venous thrombosis in systemic and monogenic vasculitis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-05-06 Federica Bello, Filippo Fagni, Giacomo Bagni, Catherine L. Hill, Aladdin J. Mohammad, Sergey Moiseev, Iacopo Olivotto, Emire Seyahi, Giacomo Emmi
-
Targeting anti-PAD4 autoantibodies in RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-05-06 Holly Webster
Findings implicate anti-PAD4 antibodies in the pathogenesis of rheumatoid arthritis.
-
Risks and benefits of immunosuppressant withdrawal in systemic lupus erythematosus Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-05-02 Catriona A. Wagner, Judith A. James
Withdrawing immunosuppressive treatment in systemic lupus erythematosus offers reduced toxicity and improved quality of life for patients in remission but carries a risk of disease reactivation. Emerging studies emphasize the importance of identifying patients who can safely discontinue therapy using clinical criteria and molecular profiling to guide personalized strategies.
-
Factors beyond urate levels for managing gout flares Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-23 Hang Korng Ea, Pascal Richette
Urate crystals alone are required but not sufficient to trigger gout flares; they can also be modulated by environmental, metabolic, genetic and epigenetic factors. Avoiding large variation in urate levels, maintaining prophylaxis until crystal clearance and initiating low-dose urate-lowering therapy are efficient strategies for disease management.
-
Understanding the causes of treatment failure is crucial for the management of axial spondyloarthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-23 Denis Poddubnyy, Xenofon Baraliakos
-
Glycosylation switch in synovial fibroblasts promotes ECM degradation Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-23 Holly Webster
Activation of N-acetylgalactosaminyltransferases in synovial fibroblasts promotes the degradation of the extracellular matrix in arthritis.
-
Targeting osteoarthritis where it hurts: the osteochondral junction Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-22 Anne-Marie Malfait, Alia M. Obeidat
-
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-17 Charlotte Jauffret, Tristan Pascart
Calcium pyrophosphate deposition (CPPD) disease is secondary to the pathological accumulation of calcium pyrophosphate (CPP) crystals inside joints and involves acute or chronic inflammatory arthritis. Epidemiological research on CPPD has been slow despite the suspected high prevalence of this condition. Here we highlight key challenges in CPPD imaging, diagnosis and nomenclature that need to be addressed
-
Fumarate drives interferon release in systemic sclerosis monocytes Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-16 Sarah Onuora
Altered metabolism of the tricarboxylic acid cycle metabolite fumarate drives activation of interferon release in systemic sclerosis monocytes, suggesting a potential therapeutic approach.
-
Upadacitinib effective for GCA in phase III trial Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-15 Sarah Onuora
In the phase III SELECT-GCA trial, upadacitinib at a dose of 15 mg daily was superior to placebo with respect to achievement of sustained remission of giant cell arteritis at 52 weeks.
-
Lipid nanoparticles with PDL1-encoding mRNA spread tolerance Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-11 Maria Papatriantafyllou
Lipid nanoparticle carriers of immunosuppressive mRNA shape tolerogenic antigen-presenting cells that inhibit arthritis progression in mice.
-
Decoding the adaptive immune repertoire for disease prediction Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-10 Laura F. Su
-
Sex- and gender-based personalized medicine in rheumatology Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-07 Elizabeth R. Volkmann, Carol Feghali-Bostwick
Although autoimmune rheumatic diseases are more prevalent in women than men, few clinical trials report findings on the basis of sex and gender. Future clinical trials should report sex and gender differences in treatment and safety outcomes in a standardized manner to improve outcomes for all patients.
-
IgG4-related disease and other fibro-inflammatory conditions Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-07 Francesco Peyronel, Emanuel Della-Torre, Federica Maritati, Maria L. Urban, Ingeborg Bajema, Nicolas Schleinitz, Augusto Vaglio
-
Sex and gender matter for TNF inhibitor therapy in RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-02 Holly Webster
Findings indicate that women and men with rheumatoid arthritis have different treatment responses to anti-TNF therapy.
-
Lupus ABC spearheading a new era of collaboration to advance lupus drug development Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-04-01 Hoang Nguyen, Teodora P. Staeva
-
The causal role of brain circuits in osteoarthritis pain Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-31 Joana Barroso, Paulo Branco, A. Vania Apkarian
-
CXCL7 promotes bone erosion in RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-28 Holly Webster
A study provides insights into the role of CXCL7 in bone erosion in rheumatoid arthritis.
-
A role for TGFβ and EBV in MIS-C pathogenesis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-28 Maria Papatriantafyllou
TGFβ compromises T cell responses against Epstein–Barr virus (EBV) and is associated with EBV reactivation in children with multisystem inflammatory syndrome (MIS-C).
-
Restoring articular cartilage: insights from structure, composition and development Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-28 Alba Pueyo Moliner, Keita Ito, Frank Zaucke, Daniel J. Kelly, Mylène de Ruijter, Jos Malda
-
Z-DNA as an inflammatory trigger in lupus Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-26 Maria Papatriantafyllou
Ultraviolet light-induced mitochondrial damage in keratinocytes leads to accumulation of Z-DNA, perpetuating type I interferon responses in cutaneous lupus.
-
Profiling synovial tissue reveals OA subgroups Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-26 Sarah Onuora
Analysis of synovial tissue samples led to the identification of inflammatory and fibrotic subgroups of osteoarthritis, which were associated with distinct fibroblast and macrophage populations.
-
Imaging inflammation with leukocyte-targeted PET tracers Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-26 Filippo Fagni
Molecular imaging techniques such as PET with the leukocyte-targeted probe 89Zr-CD45 are promising tools for rheumatology, providing a non-invasive whole-body assessment of the mechanisms that drive tissue inflammation. These techniques could improve diagnosis and disease monitoring, but further research is required before clinical implementation.
-
Oestrogens implicated in progression to arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-25 Sarah Onuora
Cumulative exposure to oestrogens over a woman’s lifetime is associated with the risk of developing seronegative inflammatory arthritis.
-
Pentose phosphate pathway metabolite restores T cell balance in SLE Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-24 Maria Papatriantafyllou
Gluconolactone promotes Treg cell function and might have potential for treating skin lesions in systemic lupus erythematosus.
-
Treating inflammatory arthritis in individuals with concomitant cancer Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-13 Maria E. Suarez-Almazor
Treating people with inflammatory arthritis and cancer is challenging given concerns around suppressing anti-tumour immunity. Targeted therapies, such as TNF inhibitors, can be safely used in patients with cancer who are in remission, but whether these treatments are safe for individuals with newly diagnosed or active cancer remains unclear.
-
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-13 David Moulin, Jérémie Sellam, Francis Berenbaum, Jérôme Guicheux, Marie-Astrid Boutet
-
Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-12 Alen Zabotti, Sibel Zehra Aydin, Paula David, Andrea Di Matteo, Dennis McGonagle
-
Hyperuricaemia and gout in the Pacific Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-11 Baptiste Gérard, Megan Leask, Tony R. Merriman, Thomas Bardin, Erwan Oehler, Aniva Lawrence, Satupaitea Viali, Samuela ‘Ofanoa, Leanne Te Karu, Lisa K. Stamp, Nicola Dalbeth, Tristan Pascart
-
Obinutuzumab effective for lupus nephritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-07 Sarah Onuora
In a phase III trial, the addition of obinutuzumab to standard therapy for lupus nephritis led to an increase in the proportion of patients with a complete renal response.
-
Stem and progenitor cells in the synovial joint as targets for regenerative therapy Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-05 Anke J. Roelofs, Jessica J. McClure, Elizabeth A. Hay, Cosimo De Bari
-
Publisher Correction: An international perspective on the future of systemic sclerosis research Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-03 David J. Abraham, Carol M. Black, Christopher P. Denton, Jörg H. W. Distler, Robyn Domsic, Carol Feghali-Bostwick, Pravitt Gourh, Monique Hinchcliff, Fred Kolling, Masataka Kuwana, Robert Lafyatis, Ulf Landegren, J. Matthew Mahoney, Javier Martin, Marco Matucci-Cerinic, Zsuzsanna H. McMahan, Ana L. Mora, Luc Mouthon, Marlene Rabinovitch, Mauricio Rojas, Kristofer Rubin, Maria Trojanowska, John Varga
Correction to: Nature Reviews Rheumatology https://doi.org/10.1038/s41584-024-01217-2, published online 14 February 2025.
-
Targeting T cell-activating NETs in uveitis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-03 Maria Papatriantafyllou
Neutrophil extracellular traps might promote intraocular infiltration of effector CD4+ T cells by inducing endothelial cell senescence in autoimmune uveitis.
-
Joint location matters for TNF inhibitor treatment in PsA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-03-03 Holly Webster
Findings show that the resolution of joint swelling in response to treatment with TNF inhibitors varies depending on the location of the joint in psoriatic arthritis.
-
TASL has a key role in SLE Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-28 Holly Webster
Two studies provide insights into the function of TASL in the pathogenesis of systemic lupus erythematosus and highlight the therapeutic potential of targeting this protein.
-
Macrophages hit a nerve in painful joint venture Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-24 Oumaima Ben Brahim, Stefan Uderhardt
-
Towards better management of sterile bone inflammation Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-20 Jürgen Braun
The first expert consensus recommendations for the treatment and diagnosis of adult sterile bone inflammation have been developed, in which the term ‘chronic non-bacterial osteitis’ is proposed as a disease definition. Will these recommendations pave the way for better diagnosis, management and treatment of this rare disease?
-
Connecting the structure and function of cartilage using spatial ‘-omics’ Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-14 Indira Prasadam, Xiwei Fan
Advances in spatial ‘-omics’, such as transcriptomics and proteomics, have provided vital insights into cartilage microenvironments, revealing cellular diversity, zonal organization and links between cartilage structure and function. Analysing cartilage using spatial ‘-omics’ could deepen the understanding of diseases such as osteoarthritis and guide the development of targeted, disease-modifying therapies
-
An international perspective on the future of systemic sclerosis research Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-14 David J. Abraham, Carol M. Black, Christopher P. Denton, Jörg H. W. Distler, Robyn Domsic, Carol Feghali-Bostwick, Pravitt Gourh, Monique Hinchcliff, Fred Kolling, Masataka Kuwana, Robert Lafyatis, Ulf Landegren, J. Matthew Mahoney, Javier Martin, Marco Matucci-Cerinic, Zsuzsanna H. McMahan, Ana L. Mora, Luc Mouthon, Marlene Rabinovitch, Mauricio Rojas, Kristofer Rubin, Maria Trojanowska, John Varga
-
A direct link between SARS-CoV-2 and bone loss Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-10 Sarah Onuora
Research demonstrates that the SARS-CoV-2 protein ORF8 drives osteoclastogenesis, establishing a direct link between viral infection and bone loss.
-
Antigen-driven T cell responses in rheumatic diseases: insights from T cell receptor repertoire studies Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-07 Jose Garrido-Mesa, Matthew A. Brown
-
Genome-wide mutagenesis reported in systemic sclerosis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-06 Carol M. Artlett, John Varga
-
Occupational dust and chemical exposures and the development of autoimmune rheumatic diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-02-05 Mandana Nikpour, Kathleen Morrisroe, Alicia Calderone, Deborah Yates, Alan Silman
-
T cells in Sjögren disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-01-31 Holly Webster
A mouse model that reflects Sjögren disease in humans provides insights into the role of regulatory T cells and type 1 helper T cells in disease pathogenesis.
-
Virome associations in autoimmunity and COVID-19 Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-01-28 Maria Papatriantafyllou
The detection of anellovirus or eHHV-6B genomes in the blood virome seems to correlate with the risk or severity of rheumatic diseases and COVID-19.
-
Opportunities and limitations of B cell depletion approaches in SLE Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-01-15 Marit Stockfelt, Y. K. Onno Teng, Edward M. Vital
-
Piezo1 as a therapeutic target for glucocorticoid-induced osteoporosis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-01-10 Holly Webster
A study implicates the Hes1–Piezo1 signalling pathway in osteocytes in the pathogenesis of glucocorticoid-induced osteoporosis and demonstrates the beneficial effects of Yoda1, a Piezo1 agonist.
-
Breaking research silos to achieve equitable precision medicine in rheumatology Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2025-01-10 Hannah C. Ainsworth, DeAnna Baker Frost, S. Sam Lim, Paula S. Ramos